Tissue Repair Limited (TRP) is an advanced biotechnology company specialising in second-generation wound healing agents. Currently in the genuine Phase 3 clinical stage, the company is preparing to start its Phase 3 programme for chronic wounds with its lead drug candidate, TR987. Additionally, Tissue Repair focuses on commercialising TR Pro+â„¢, a topical gel designed to accelerate healing and enhance skin quality following cosmetic procedures.